Phase III clinical trials have thoroughly assessed the safety and efficacy of these TKIs and PD-L1 monoclonal antibodies [59] in combination with standard-of-care chemotherapy for first-line treatment in NSCLC patients (Table 4). The gene discussed is CD274; the disease is non-small cell lung carcinoma.